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Introduction  
To help finance its historic expansions of insurance 
coverage, the Patient Protection and Affordable Care 
Act (ACA) includes several provisions aimed at slowing 
the rate of growth of personal health expenditures. This 
goal is addressed partly by reductions in payments to 
health care providers and partly by future reductions in 
the tax subsidies for extremely generous insurance 
plans—often referred to as “Cadillac plans”—to increase 
the price sensitivity of consumers. Another ACA strategy 
is a focus on disease prevention to reduce the future 
need for care. According to polling conducted during the 
2009 health care reform debate, the public believes that 
disease prevention is a key component of improving the 
long-term prospect of the nation’s health care system,1 
and the rhetoric about reform has often included 
references to prevention. However, not until the 
passage of the ACA was health care reform linked to 
funding for public health and prevention. 
 
The ACA includes provisions supporting coverage of 
clinical preventive services in insurance benefit 
packages and innovative new funding for public health 
through the Prevention and Public Health Fund (PPHF). 
The use of the fund is flexible but it will be guided by the 
National Prevention Strategy, which was published in 
June 2011.2  Although current funding decisions had to 
be made before the strategy was finalized, they are 
consistent with its goals, and substantial PPHF 
expenditures have been dedicated to funding evidence-
based interventions to address tobacco control, obesity 
prevention, better nutrition, and physical activity.
3
 Taken 
as a group, these interventions target primarily chronic 
diseases like diabetes, hypertension, heart disease, 
stroke, and renal disease. Recent research has 
demonstrated just how costly this limited set of diseases 
is to the U.S. health care system.4  The primary focus of 
this brief is to explore the contribution that disease 
prevention efforts can make toward bending the cost 
curve.  
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A growing body of research has demonstrated that 
community-based approaches can be successful in 
changing behaviors and reducing risk factors for these 
diseases, especially if implemented with the knowledge 
and participation of clinicians.5  It is specifically this type 
of lifestyle-modification interventions that a significant 
portion of the PPHF’s Community Transformation 
Grants have targeted.6 
 
Some large private businesses have recognized the 
potential savings from disease prevention and are 
developing lifestyle modification or wellness programs.7 
The impact of these programs, however, is limited to the 
population employed by such firms, which leaves 
several important segments of the population 
unaffected. Economies of scale in wellness programs 
make widespread private sector adoption unlikely. The 
case for public intervention in this area is bolstered by 
the fact that the greatest impact of disease prevention 
on spending will accrue to the Medicare and Medicaid 
programs.8  Further, the aging of the population means 
that the Medicare costs associated with this set of 
diseases will only grow. In the current debate over the 
future fiscal status of the federal government, cutting a 
set of evidence-based programs that can relieve 
pressure on the largest contributor to fiscal imbalance 
over the long run seems short-sighted at best. 
 
The following overview outlines several promising 
approaches targeted in the first round of funding for the 
PPHF. It enumerates the benefits that these 
interventions can produce for both health and cost 
containment and that would be foregone if the PPHF 
were eliminated either through a full repeal of the ACA 
or through targeted budget cuts. Then, based on 
estimations of the cost of illness by age, it explores what 
reducing or eliminating the PPHF would mean for 
Medicare and Medicaid over the next 20 years.  
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 Promising Initiatives in Chronic Disease 
Prevention 
The literature abounds with examples of the potential of 
primary and community-based prevention. These 
initiatives indicate the level of results that could be 
expected from PPHF-funded programs and the progress 
that would be forgone if this ACA component were to be 
eliminated.  
Diabetes Prevention 
The Diabetes Prevention Program (DPP) is a large 
randomized clinical trial targeted at adults who have a 
high risk of developing diabetes. Early results showed 
that structured lifestyle intervention programs targeted 
at people identified by relatively simple diagnostic 
screening can reduce the incidence rate of diabetes by 
more than half.9  Follow-up studies showed that these 
gains could be maintained over time.10 The approach 
was designed to be implemented in physicians’ offices 
by medical professionals. Following its success, 
however, it has been adapted to a community setting 
where trained nonclinicians can implement the 
intervention in the community at a cost that is 
approximately 12 percent of the cost of the original DPP 
intervention.11  Interim measures of behavior 
modification and weight loss are quantitatively similar to 
those achieved by the DPP approach, but long-run 
results have not yet been quantified. Although diabetes 
is the focus of these studies, the weight loss, increased 
physical activity, and improved diet that these 
interventions produce have also been shown to reduce 
blood pressure, a known precursor of stroke, heart 
disease, and kidney disease.  
 
Smoking Cessation 
Smoking is associated not only with the incidence of 
several cancers but also with increased incidence of 
cardiovascular disease, hypertension, and stroke. In 
another randomized clinical trial, the traditional 
approach of clinician identification of smokers and brief 
in-office counseling was compared with a “cessation 
support” approach that included faxed referrals to a 
community-based “Quitline” of smokers identified as 
ready to try quitting.12  The addition of an easy referral 
method and the availability of the link to the community 
program were associated with improved clinician 
provision of smoking cessation counseling. Other 
research shows that receipt of clinician counseling 
promotes smoking cessation.13 
 
HIV Prevention 
A recent large clinical trial on the transmission of human 
immunodeficiency virus (HIV) concluded early when 
researchers determined that the evidence was clear that 
early diagnosis and treatment of HIV-positive individuals 
with oral antiretroviral medicines reduced the 
transmission of the virus by 96 percent.
14 
 This landmark 
study highlights the importance of screening, one of the 
clinical preventive services included as a covered 
benefit under the ACA.  
 
Multifactorial Community Interventions  
Community-wide interventions that target nutrition and 
physical activity in a broad program of change across 
various sectors (e.g., schools, restaurants, built 
environment) have shown positive effects on reducing 
the rate of increase in obesity at relatively low cost. 
Shape Up Somerville (Massachusetts) provided 
evidence that such multifactorial interventions could 
slow the growth of child obesity.15  Evidence from other 
programs confirms the potential of this model. For 
example, from an initial base of 10 communities in 
France, the EPODE program has grown to cover 113 
communities.16  EPODE promotes healthy eating, a 
more active lifestyle, and reduction in smoking and 
stress. It has documented improvements in health-
related lifestyle choices and a leveling off of maternal 
and child obesity.17 
 
Targeting Health Disparities  
Racial and Ethnic Approaches to Community Health 
(REACH) is a Centers for Disease Control and 
Prevention (CDC)-sponsored program to reduce health 
disparities through community-based participatory 
approaches. Over four years, this program has shown 
results such as decreases in smoking among Asian 
Americans, increases in cholesterol screening among 
Hispanics and African Americans, and increases in 
breast and cervical cancer screening.18 
 
 
 
The Cost of Ignoring Chronic Disease 
Prevention 
If funding is not available to support these and other 
primary prevention initiatives, the country can expect to 
see at best a continuation of current trends in chronic 
disease. People with chronic disease have higher 
medical care costs. The difference between the cost of 
care for people with chronic disease and those without 
can be thought of as the “excess costs” associated with 
chronic disease. One of the benefits of primary 
prevention programs such as those funded under the 
PPHF would be a reduction in excess medical costs. 
(Other benefits include reduced absenteeism and 
improved productivity at work and school, which are not 
addressed here.) To the extent that these excess costs 
are currently publicly financed through Medicare and 
Medicaid, reducing these costs would offset the cost of 
funding the PPHF.  
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 Based on our analysis of spending by two population 
groups—seniors (age 65 and above) and baby boomers 
(ages 45–64)—using data from the Medical Expenditure 
Panel Survey (MEPS), we estimate that the annual 
excess medical care cost of four diseases associated 
with obesity and smoking (type 2 diabetes, 
hypertension, heart disease, and stroke) is currently 
$238 billion. Of this total, we estimate that $134 billion is 
financed by the Medicare and Medicaid. More alarming, 
however, is the fact that the prevalence of each of these 
diseases has grown significantly in recent years and is 
projected to continue growing.19  Such projections are 
supported by the dramatic growth in obesity and 
overweight among Americans of all ages. 20 
 
Table 1 shows baseline age-specific prevalence trends 
in each disease based on recent trends in type 2 
diabetes prevalence observed by the CDC21 and 
projections of hypertension, heart disease, and stroke 
produced by the American Heart Association.22  Among 
the diseases studied, diabetes is growing the fastest 
with an annualized growth rate of 3.5 percent. If current 
trends continue, diabetes prevalence will approximately 
double over the next 20 years. Hypertension is the 
highest prevalence disease among the four but is 
growing more slowly (0.7 percent per year). The 
baseline projection is that by 2030, the prevalence of 
hypertension will reach 33.1 percent for 45- to 64-year-
olds and 57.4 percent for those age 65 and older. Heart 
disease prevalence is growing the most slowly of the 
four conditions (0.5 percent per year), and by 2030 is 
expected to reach a prevalence of 11.2 percent and 
33.9 percent in the younger and older age groups, 
respectively. Stroke has lower prevalence than the other 
three conditions, but it is second only to diabetes in the 
relative rate of growth (1.1 percent per year). 
Prevalence of stroke is projected to increase to 1.6 
percent and 7.4 percent for the older and younger 
groups, respectively.  
 
Left unchecked, health care costs associated with these 
conditions will continue to grow, affecting not just public 
sector budgets but also private sector costs and 
competitiveness. Even assuming no increase in the 
price of services or per capita utilization rates by 
persons of a given health profile, the projected 
increases in the prevalence of these four diseases imply 
an increase in total excess health care cost from $238.3 
billion per year in 2010 to $466.5 billion per year in 
2030. Of that total, $293.7 billion will be paid annually by 
Medicare and Medicaid. 
 
 
The Potential Impact of Primary Prevention 
Primary prevention approaches like those discussed 
above have been demonstrated effective at slowing the 
progression of each of these conditions. The DPP, for 
example, has reduced the rate of onset of diabetes 
among its participants by approximately 58 percent, with 
even higher rates of success (71 percent) among those 
over age 60.23  Starting from this level of effectiveness 
in disease prevention, Table 2 shows three alternative 
scenarios for the growth in disease prevalence. The top 
panel presents prevalence projections if the current 
growth rates of these four diseases are cut by 50 
percent. The second, more modest scenario assumes 
that we are only half as successful at slowing disease 
growth, reducing the growth rates by 25 percent. The 
third scenario assumes a minimal level of success, 
where the current rate of increase is slowed by only 5 
percent. 
 
It is important to note that we do not purport to reduce 
disease prevalence from current levels, but rather to 
simply slow the current rate of growth largely by 
preventing some fraction of new cases. Even with the 
reductions modeled here, by 2030 each disease will 
have increased in prevalence, albeit by less than would 
have been the case without the modeled reduction. For 
this reason, each of the prevalence scenarios is 
associated with an increase in excess medical care 
costs, although each is associated with a smaller 
increase than would be seen without prevention 
interventions. These excess costs can be thought of as 
the cost in government health care expenditures of 
failure to address the growth in chronic disease 
prevalence.  
Age group Baby Boomers Seniors 
Year Diabetes 
Heart 
Disease 
Hyper-
tension Stroke Diabetes 
Heart 
Disease 
Hyper- 
tension Stroke 
2010 13.4% 9.7% 30.1% 1.3% 26.9% 29.3% 52.1% 5.9% 
2015 16.0% 10.0% 30.8% 1.3% 32.1% 30.4% 53.4% 6.3% 
2020 19.0% 10.4% 31.6% 1.4% 38.3% 31.5% 54.7% 6.6% 
2025 22.7% 10.8% 32.3% 1.5% 45.7% 32.7% 56.0% 7.0% 
2030 27.1% 11.2% 33.1% 1.6% 54.6% 33.9% 57.4% 7.4% 
Source: Author’s calculations based on CDC estimates of current prevalence and recent trends in type 2 diabetes and projected 
growth rates in heart disease, hypertension, and stroke from the American Heart Association. Age-specific prevalence rates for hy-
pertension, heart disease, and stroke were estimated using the 2003–2008 Medical Expenditure Panel Survey. 
Table 1: Baseline Trends in Prevalence of Selected Chronic Disease 
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Using the baseline rates of disease prevalence from 
Table 1 and the simulated rates from Table 2, Table 3 
shows the difference in annual Medicare and Medicaid 
spending that would result from the three alternative 
prevalence scenarios. If we assume that the level of 
success of the DPP can be replicated nationwide, then 
the cost of eliminating such an investment in disease 
prevention would be quite large. In five years, combined 
Medicare and Medicaid spending will be $6.6 billion per 
year higher without these programs. Over time, these 
excess costs will grow ever larger: by 2030, spending by 
the two public health insurance programs could be 
nearly $50 billion more per year. 
 
Under a more modest assumption (shown in the second 
panel) that bringing disease prevention programs to 
scale would result in only half the reduction in growth 
rates demonstrated in studies, the savings are still 
substantial. They easily outweigh the annual 
appropriation to the PPHF within the first five years and 
dwarf that investment by more than tenfold by 2030. 
Even assuming that prevention efforts are only 
minimally effective at slowing the rates of disease 
growth (shown in the third panel), the return on the 
PPHF investment is still positive. Thus, even under this 
scenario, eliminating PPHF funding would still end up 
affecting the public purse on an annual basis.  
 
Furthermore, if these estimates of PPHF benefits 
included the effect on other sources of health care 
spending, such as private insurance expenditures and 
individual out-of-pocket costs, under the most optimistic 
scenario these savings would reach nearly $10 billion 
per year within five years and nearly $70 billion per year 
within 20 years. Under the least optimistic assumption, 
system-wide savings due to prevention would be $1 
billion per year within five years and nearly $8 billion per 
year within 20 years.  
a. Slow disease growth by 50%  
Age group 45–64 65+  
Year Diabetes 
Heart  
Disease 
Hyper-
tension Stroke Diabetes 
Heart  
Disease 
Hyper-
tension Stroke  
2010 13.4% 9.7% 30.1% 1.3% 26.9% 29.3% 52.1% 5.9%  
2015 14.6% 9.8% 30.5% 1.3% 29.4% 29.8% 52.8% 6.1%  
2020 16.0% 10.0% 30.8% 1.3% 32.1% 30.4% 53.4% 6.3%  
2025 17.4% 10.2% 31.2% 1.4% 35.1% 30.9% 54.0% 6.4%  
2030 19.0% 10.4% 31.6% 1.4% 38.3% 31.5% 54.7% 6.6%  
                   
b. Slow disease growth by 25%  
Age group 45–64 65+  
Year Diabetes 
Heart  
Disease 
Hyper-
tension Stroke Diabetes 
Heart  
Disease 
Hyper-
tension Stroke  
2010 13.4% 9.7% 30.1% 1.3% 26.9% 29.3% 52.1% 5.9%  
2015 15.3% 9.9% 30.7% 1.3% 30.7% 30.1% 53.1% 6.2%  
2020 17.4% 10.2% 31.2% 1.4% 35.1% 30.9% 54.0% 6.4%  
2025 19.9% 10.5% 31.8% 1.4% 40.1% 31.8% 55.0% 6.7%  
2030 22.7% 10.8% 32.3% 1.5% 45.7% 32.7% 56.0% 7.0%  
                    
c. Slow disease growth by 5%  
Age group 45–64 65+  
Year Diabetes 
Heart  
Disease 
Hyper-
tension Stroke Diabetes 
Heart  
Disease 
Hyper-
tension Stroke  
2010 13.4% 9.7% 30.1% 1.3% 26.9% 29.3% 52.1% 5.9%  
2015 15.8% 10.0% 30.8% 1.3% 31.8% 30.3% 53.3% 6.2%  
2020 18.7% 10.4% 31.5% 1.4% 37.7% 31.4% 54.6% 6.6%  
2025 22.1% 10.7% 32.2% 1.5% 44.5% 32.5% 55.8% 6.9%  
2030 26.2% 11.1% 33.0% 1.6% 52.7% 33.7% 57.1% 7.3%  
Table 2: Disease Trends Assuming Varying Success in Disease Prevention 
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The benefits of reduced chronic disease are found not 
only in medical care expenditures.24  It has been 
estimated that the benefits to employers of reduced 
absenteeism and improved productivity of workers are 
nearly as high as the reduction in health costs. If one 
also includes these benefits to society in the 
calculations, even the modest reduction in disease 
prevalence results in a positive return on investment 
within a short time frame. The benefit to individuals of 
improved health and quality of life is difficult to quantify, 
but is nonetheless real.  
 
 
Discussion 
As has been rigorously demonstrated by the recent 
Oregon health experiments, expanding insurance 
coverage has unambiguously positive effects on access 
and health for those who would otherwise be 
uninsured.25  The primary goal of the ACA pursues this 
goal of expanding access to quality health care through 
a combination and public and private insurance plans. 
Along with that goal, however, the ACA recognizes the 
urgency of controlling the growth in chronic disease, 
both for the benefits to individuals of good health and for 
the effect on national medical care costs and worker 
productivity. The ACA includes the PPHF as a means of 
identifying and investing in effective primary prevention 
interventions. The experience of demonstration projects 
using this type of approach suggests huge potential 
returns on investment. But even if effectiveness is 
reduced significantly as such projects are scaled up—
even to just one tenth the experimental effect—our 
analysis suggests that these investments can still pay 
for themselves. Large employers’ investment in 
prevention for their workers suggests that they believe 
that the contribution to good health and worker 
productivity will also be significant.26 
 
The growth in per capita medical care spending in the 
United States has dramatically outpaced spending in 
other industrialized countries, even as universal access 
to care has lagged. In large part, this growth is a result 
of growing prevalence of chronic disease. The result is 
accelerated growth in both public and private sector 
expenditures on health. Therefore, bringing disease 
growth under control is essential if the United States is 
to remain competitive in the world economy. Addressing 
the problem of cost growth will require multiple tools, 
and removing effective disease prevention approaches 
like the PPHF from our set of tools would simply 
increase the size of the problem. 
Table 3: Annual Program Savings Assuming Reductions in Growth Rates of Chronic Disease Prevalence 
a. Slow disease growth by 50% 
Year 
Medicare Medicaid Total 
Billions of $ (2011) 
2015 4.4 2.1 6.6 
2020 11.1 5.1 16.2 
2025 20.9 9.2 30.1 
2030 34.2 14.7 48.9 
    
b. Slow disease growth by 25% 
Year 
Medicare Medicaid Total 
Billions of $ (2011) 
2015 2.3 1.1 3.3 
2020 5.7 2.7 8.4 
2025 11.0 4.9 15.9 
2030 18.3 7.9 26.2 
        
c. Slow disease growth by 5% 
Year 
Medicare Medicaid Total 
Billions of $ (2011) 
2015 0.5 0.2 0.7 
2020 1.2 0.5 1.7 
2025 2.3 1.0 3.3 
2030 3.9 1.7 5.5 
© 2011, The Urban Institute Health Policy Center • www.healthpolicycenter.org page 6  
 Notes 
1. “Americans Overwhelmingly Support Investment in 
Prevention: Disease Prevention Plays a Lead Role in Health 
Care Reform,” Greenberg Quinlan Rosner Research & Public 
Opinion Strategies, May 18, 2009. http://
healthyamericans.org/assets/files/health-reform-poll-
memo.pdf  
 
2. National Prevention Council, “National Prevention Strategy: 
America’s Plan for Better Health and Wellness,” June 2011. 
http://www.healthcare.gov/center/councils/nphpphc/strategy/
report.html  
 
3. “The Affordable Care Act’s Prevention and Public Health 
Fund in Your State,” HealthCare.gov, February 2011. http://
www.healthcare.gov/news/factsheets/
prevention02092011a.html 
 
4. R. DeVol et al., “An Unhealthy America: The Economic 
Burden of Chronic Disease—Charting a New Course to Save 
Lives and Increase Productivity and Economic Growth,” 
October 2007. http://www.milkeninstitute.org/pdf/
chronic_disease_report.pdf 
 
5. B. A. Ormond, R. R. Bovbjerg, and T. A. Waidmann, 
“Synergies Between Clinical and Community 
Prevention” (forthcoming, 2011).  
 
6. “Prevention and Public Health Fund: Community 
Transformation Grants to Reduce Chronic Disease,” 
HealthCare.gov, May 13, 2011. http://www.healthcare.gov/
news/factsheets/grants05132011a.html.  
 
7. P. Wechsler, “UnitedHealth Diabetes Plan Gives Savings 
Congress Snubbed,” Bloomberg News, April 21, 2011. 
 
8. B. Ormond et al., “Potential National and State Health Care 
Savings from Primary Prevention,” American Journal of Public 
Health 101, no. 1 (January 2011):157–164. 
 
9. Diabetes Prevention Program Research Group, “The 
Diabetes Prevention Program (DPP): Description of Lifestyle 
Intervention,” Diabetes Care 25, no. 12 (2002): 2165–71; 
Diabetes Prevention Program Research Group, “Reduction in 
the Incidence of Type 2 Diabetes with Lifestyle Intervention or 
Metformin,” New England Journal of Medicine 346, no. 6 
(2002): 393–403. 
 
10. Diabetes Prevention Program Research Group, “10-Year 
Follow-up of Diabetes Incidence and Weight Loss in the 
Diabetes Prevention Program Outcomes Study,” The Lancet 
374, no. 9702 (2009):1677–86. 
 
11. R. T. Ackerman and D. G. Marrero, “Adapting the Diabetes 
Prevention Program Lifestyle Intervention for Delivery in the 
Community: The YMCA Model,” The Diabetes Educator 33, 
no. 1 (2008): 69–78; R. T. Ackermann, E. A. Finch, E. 
Brizendine, H. Zhou, and D. G. Marrero, “Translating the 
Diabetes Prevention Program into the Community: The 
DEPLOY Pilot Study,” American Journal of Preventive 
Medicine 35, no. 4 (2008): 357–63. 
 
12. S. F. Rothemich et al., “Promoting Primary Care Smoking 
Cessation Support with Quitlines: The Quitline Randomized 
Clinical Trial,” American Journal of Preventive Medicine 38, 
no. 4 (April 2010): 367–76.  
 
13. C. L. Duncan et al., “Quitting Smoking: Reasons for Quitting  
 
 
and Predictors of Cessation among Medical Patients,” Journal 
of General Internal Medicine 7, no.4 (July–August 1992): 398-
404. 
 
14. “Treating HIV-infected People with Antiretrovirals Protects 
Partners from Infection: Findings Result from NIH-funded 
International Study,” NIH News, May 12, 2011. http://
www.niaid.nih.gov/news/newsreleases/2011/Pages/
HPTN052.aspx 
 
15. C. D. Economos et al., “A Community Intervention Reduces 
BMI Z-score in Children: Shape Up Somerville First Year 
Results.” Obesity (Silver Spring) 15, no. 5 (2007): 1325–36. 
 
16. H. Westley, “Thin Living,” British Medical Journal 335 (2007): 
1236–1237. 
 
17. S. Raffin, “Together, We Can Prevent Childhood Obesity,” 
EPODE presentation. http://www.ehfg.org/fileadmin/ehfg/
Website/Archiv/2005/Power_Points/Forum_1/F1-
II_Raffin_final.pdf 
 
18. REACH U.S., “Findings Solutions to Health Disparities: At a 
Glance 2010, ”Centers for Disease Control and Prevention, 
Chronic Disease Control and Health Promotion. http://
www.cdc.gov/chronicdisease/resources/publications/AAG/
reach.htm.  
 
19. R. DeVol et al., “An Unhealthy America.” 
 
20. “F as in Fat: How Obesity Threatens America’s Future,” Trust 
for America’s Health, July 2011. http://healthyamericans.org/
assets/files/TFAH2011FasInFat10.pdf  
 
21. “Diabetes Data and Trends,” Centers for Disease Control and 
Prevention, Accessed July 1, 2011. http://apps.nccd.cdc.gov/
DDTSTRS/default.aspx 
 
22. P. A. Heidenreich et al., “Forecasting the Future of 
Cardiovascular Disease in the United States: A Policy 
Statement From the American Heart Association,” Circulation 
123 (January 2011): 933–944. http://circ.ahajournals.org/
content/123/8/933.full.pdf+html?sid=a2b44ebb-2c38-4d6f-
9981-79a197b5c250  
 
23. Diabetes Prevention Program Research Group, “Reduction in 
the Incidence of Type 2 Diabetes with Lifestyle Intervention or 
Metformin,” New England Journal of Medicine 346, no. 6 
(February 2002): 393–403; Diabetes Prevention Program 
Research Group, “Within-Trial Cost-Effectiveness of Lifestyle 
Intervention or Metfaormin for the Primary Prevention of Type 
2 Diabetes,” Diabetes Care 26, no. 9 (September 2003): 2518
–23.  
 
24. R. Z. Goetzel et al., “The Health And Productivity Cost 
Burden of the ‘Top 10’ Physical and Mental Health Conditions 
Affecting Six Large U.S. Employers,” Journal of Occupational 
and Environmental Medicine 46 (2003): 398–412. 
 
25. A. Finkelstein et al., “The Oregon Health Insurance 
Experiment: Evidence from the First Year,” NBER Working 
Paper 17190, July 2011. http://www.nber.org/papers/w17190  
 
26. Pitney Bowes, for example, has been a leader in employee 
wellness programs. http://news.pb.com/press_kits.cfm?
presskit_id=2  
 
© 2011, The Urban Institute Health Policy Center • www.healthpolicycenter.org page 7  
 
The views expressed are those of the authors and should not be attributed to the Urban Institute, its 
trustees, or its funders.  
About the Authors and Acknowledgements 
Timothy A. Waidmann, PhD, is a Senior Fellow, Barbara A. Ormond, PhD, is a Senior Research Asso-
ciate, and Randall R. Bovbjerg, JD, is a Senior Fellow at the Urban Institute’s Health Policy Center. 
The research in this paper was funded by the Robert Wood Johnson Foundation.  The authors wish to 
thank Brenda Henry and Joe Marx at the Foundation for helpful comments on an earlier draft of this 
paper. 
 
About the Urban Institute 
The Urban Institute is a nonprofit, nonpartisan policy research and educational organization that ex-
amines the social, economic, and governance problems facing the nation. For more information, visit  
http://www.urban.org.   
 
About the Robert Wood Johnson Foundation 
The Robert Wood Johnson Foundation focuses on the pressing health and health care issues facing 
our country. As the nation’s largest philanthropy devoted exclusively to improving the health and 
health care of all Americans, the Foundation works with a diverse group of organizations and individu-
als to identify solutions and achieve comprehensive, meaningful, and timely change. For nearly 40 
years the Foundation has brought experience, commitment, and a rigorous, balanced approach to the 
problems that affect the health and health care of those it serves. When it comes to helping Americans 
lead healthier lives and get the care they need, the Foundation expects to make a difference in your 
lifetime. For more information, visit http://www.rwjf.org  
